The largest opportunities for organ regeneration lie in diseases/disorders of the bone marrow, kidneys, liver, pancreas, and small intestine. Market segments covered by this report include bioartificial kidneys and livers/liver regeneration products, bone marrow regeneration products, pancreas regeneration products, and small intestine replacement products. Various tissue engineering technologies including genes, scaffolds, stem cells, and xenotransplants are being researched for applications in organ regeneration.
This new report also provides a clinical overview of selected diseases/disorders that are amenable to treatment with tissue-engineered and cell transplantation products and includes the most up-to-date incidence and prevalence figures.
This report is the fifth in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. The final report in this series will provide an analysis of the U.S. market for tissue-engineered skin replacement and skin substitute products.
EXECUTIVE SUMMARY i. Clinical Applications for Organ Regeneration a. Bone Marrow Disease b. Diabetes c. Intestinal Disorders d. Kidney Disease e. Liver Disease ii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iii. Technologies Under Development for Organ Regeneration a. Bone Marrow Regeneration Technologies b. Intestine Regeneration Technologies c. Kidney Regeneration Technologies d. Liver Regeneration Technologies e. Pancreas Regeneration Technologies f. Bioartificial Organ Technologies iv. Market Analysis v. Methodology Exhibit ES-1: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 1. CLINICAL OVERVIEW OF TISSUE ENGINEERING APPLICATIONS FOR ORGAN REGENERATION 1.1 Disease Incidence 1.1.1 Bone Marrow Disease 184.108.40.206 Aplastic Anemia 220.127.116.11 Leukemia and Lymphoma 1.1.2 Diabetes 1.1.3 Intestinal Disorders 18.104.22.168 Intestinal Pseudo-Obstruction 22.214.171.124 Microvillus Inclusion Disease 126.96.36.199 Short Bowel Syndrome 1.1.4 Kidney Disease 1.1.5 Liver Disease 1.2 Existing Therapies 1.2.1 Ex Vivo Systems 188.8.131.52 Kidney Dialysis Systems 1.2.2 Organ Transplantation 184.108.40.206 Bone Marrow Transplantation 220.127.116.11 Kidney Transplantation 18.104.22.168 Liver Transplantation 22.214.171.124.1 Split Cadaveric Livers 126.96.36.199.2 Liver Segments from Living Donors 188.8.131.52 Pancreas Transplantation 184.108.40.206 Intestinal Transplantation Exhibit 1-1: Incidence and Prevalence of Major Organ Diseases/Disorders Exhibit 1-2: Organ Transplantation, by Type, Procedure Volumes, and Waiting List Exhibit 1-3: Average Estimated First-Year Billed Charges, Per Transplant 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 220.127.116.11 Collagen 18.104.22.168 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 22.214.171.124 Deoxyribonucleic Acid Transfection Vectors 126.96.36.199 Genetically Manipulated Cells 188.8.131.52 Three-Dimensional Polymer Technology 184.108.40.206 Transgenics 220.127.116.11 Fibroblasts 18.104.22.168 Immortalized Neural Stem Cells 22.214.171.124 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 126.96.36.199 Flatbed Perfusion Systems 188.8.131.52 Hollow Fiber Bioreactor Systems 184.108.40.206 Cell Suspension Systems 220.127.116.11 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR ORGAN REGENERATION PRODUCTS 3.1 Emerging Technologies and Products 3.1.1 Genes 3.1.2 Scaffolds 3.1.3 Stem Cells 3.1.4 Xenotransplants 3.1.5 Bone Marrow 18.104.22.168 Gamida Cell 22.214.171.124 Osiris Therapeutics 126.96.36.199 SituGen 188.8.131.52 University of Texas M.D. Anderson Cancer Center and the ViaCord Research Institute/ViaCord/PerkinElmer 3.1.6 Intestine 3.1.7 Kidney 184.108.40.206 Tengion 3.1.8 Liver 220.127.116.11 Cytonet 18.104.22.168 StemCells 22.214.171.124 Vesta Therapeutics 3.1.9 Pancreas 126.96.36.199 BioTime 188.8.131.52 Cerco Medical 184.108.40.206 Geron 220.127.116.11 Juvenile Diabetes Research Foundation 18.104.22.168 Osiris Therapeutics 22.214.171.124 ViaCyte 126.96.36.199 StemCells 188.8.131.52 TheraCyte 184.108.40.206 Transition Therapeutics 220.127.116.11 ViaCord/PerkinElmer 18.104.22.168 Vitro Biopharma/Vitro Diagnostics 3.2 Artificial Organ Technologies 3.2.1 Bioartificial Kidney 3.2.2 Bioartificial Liver 22.214.171.124 Excorp Medical 126.96.36.199 Gambro 188.8.131.52 HepaLife Technologies 184.108.40.206 Hep-Art Medical Devices 220.127.116.11 Hybrid Organ 18.104.22.168 Vital Therapies 22.214.171.124 Xenogenics/MultiCell Technologies 3.2.3 Artificial Pancreas 126.96.36.199 Juvenile Diabetes Research Foundation 188.8.131.52 Medtronic 3.3 Market Analysis 3.3.1 Market Drivers 3.3.2 Market Limiters 3.4 Competitors Exhibit 3-1: 2010, Selected Emerging Treatment Products for Liver Failure Exhibit 3-2: 2010, Selected Emerging Treatment Products for Pancreatic Failure Exhibit 3-3: 2010, Selected Bioartificial and Artificial Organ Products Exhibit 3-4: Medtronic's STAR 3 Study Results Exhibit 3-5: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 Exhibit 3-6: Organ Regeneration Technologies, by Indication, 2009 and 2019 4. COMPANY PROFILES 4.1 BioTime, Inc. 4.2 Cerco Medical LLC 4.3 Cytonet GmbH & Co. KG 4.4 Geron Corporation 4.5 Osiris Therapeutics, Inc. 4.6 PerkinElmer, Inc. 4.7 StemCells, Inc. 4.8 Tengion, Inc. 4.9 Vesta Therapeutics, Inc. 4.10 ViaCyte, Inc. APPENDIX: COMPANY LISTING